CytRx rallies after conference presentation

CytRx (CYTR) trades 6% higher in premarket action.

Investors seem pleased with Tuesday's presentation at the LD MICRO Main Event Conference in L.A.

The company discussed aldoxorubicin, reviewed some data from on-going Phase 2 trials, and talked a bit about the upcoming Phase 3 study (Q1 2014 is planned start).

CYTR also presented a timeline, outlining "numerous upcoming catalysts."

Those interested can view the full presentation here.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs